Back to results
US 7,001,912 B2Granted
HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use
AssigneeAgouron Pharmaceuticals, Inc.
InventorsAtsuo Kuki, Xinqiang Li, Michael Bruno Plewe, Hai Wang, Junhu Zhang
Life of this patent
Estimating the term…
Abstract
Beta-carboline hydroxamic acid compounds represented by formula (I) are described. The beta-carboline hydroxamic acid compounds and compositions containing those compounds may be used to inhibit or modulate the activity of HIV integrase enzyme and to treat HIV integrase-mediated diseases and conditions.
Claims14
A compound of formula (I),
- wherein:
- R1, R2, R3, R4, R5, and R6 are independently selected from hydrogen, halogen, C1–C6 alkyl, alkoxy C1–C6 alkyl, C2–C6 alkenyl, C2–C6 alkynyl, —ORc, —NO2, and —N(Rc)2;
- each Rc is independently selected from hydrogen, C1–C6 alkyl, C2–C6 alkenyl, and C2–C6 alkynyl;
- R7 is C1–C6 alkyl, C2–C6 alkenyl, or C2–C6 alkynyl, all of which are optionally substituted by one or more substituents independently selected from halogen, C1–C6 alkyl, C2–C6 alkenyl, C2–C6 alkynyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl, wherein said aryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one or more substituents independently selected from halogen, C1–C6 alkyl, C2–C6 alkenyl, and C2–C6 alkynyl;
- R8 and R9 are independently selected from hydrogen, C1–C6 alkyl, C2–C6 alkenyl, and C2–C6 alkynyl, wherein said alkyl, alkenyl, and alkynyl are optionally substituted with one or more substituents independently selected from halogen, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl group, wherein said aryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one or more substituents independently selected from halogen, C1–C6 alkyl, C2–C6 alkenyl, and C2–C6 alkynyl;
- and
- pharmaceutically acceptable salts and solvates thereof.
4 more elements
Dependencies are inferred from the claim text.